Boston Scientific joined the space earlier this year when it agreed to acquire a remaining stake in IVL specialist Bolt Medical for $664m. In April, Bolt Medical received US Food and Drug ...

Boston Scientific’s $664m bet on Bolt Medical has paid off, as the company’s intravascular lithotripsy (IVL) system gains US Food and Drug Administration (FDA) clearance. Whilst neither Bolt ...

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular lithotripsy (IVL) system, positioning ...

Abbott announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the treatment ...